Home/ Stocks/ ARTV

Artiva Biotherapeutics, Inc. Common Stock

ARTV XNAS

$10.89 -1.02 (-8.15%) ▼ 15-min delayed

Open

$12.05

High

$12.68

Low

$10.20

Volume

5.29M

Market Cap

$269.16M

About Artiva Biotherapeutics, Inc. Common Stock

Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 106 Website →

Key Financials

Period	Revenue	Net Income	EPS
TTM 2025	$0	$-83,865,000	$-3.43
FY 2025	$0	$-83,865,000	$-3.43
Q3 2025	$0	$-21,528,000	$-0.88
Q2 2025	$0	$-21,254,000	$-0.87

Earnings & Analyst Ratings

Next Earnings: Tue, Aug 4, 2026

Calendar →

Related Market News

No specific coverage for ARTV yet. Check out our latest market news or earnings calendar.

Get ARTV Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Artiva Biotherapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.